GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pfizer Inc (NYSE:PFE) » Definitions » Cyclically Adjusted Price-to-FCF

Pfizer (Pfizer) Cyclically Adjusted Price-to-FCF : 8.22 (As of Apr. 27, 2024)


View and export this data going back to 1951. Start your Free Trial

What is Pfizer Cyclically Adjusted Price-to-FCF?

As of today (2024-04-27), Pfizer's current share price is $25.40. Pfizer's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $3.09. Pfizer's Cyclically Adjusted Price-to-FCF for today is 8.22.

The historical rank and industry rank for Pfizer's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

PFE' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 8.17   Med: 14.39   Max: 21.47
Current: 8.19

During the past years, Pfizer's highest Cyclically Adjusted Price-to-FCF was 21.47. The lowest was 8.17. And the median was 14.39.

PFE's Cyclically Adjusted Price-to-FCF is ranked better than
91.36% of 324 companies
in the Drug Manufacturers industry
Industry Median: 32.655 vs PFE: 8.19

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Pfizer's adjusted free cash flow per share data for the three months ended in Dec. 2023 was $0.743. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $3.09 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Pfizer Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Pfizer's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pfizer Cyclically Adjusted Price-to-FCF Chart

Pfizer Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.05 15.25 20.86 15.98 9.33

Pfizer Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.98 12.64 11.60 10.61 9.33

Competitive Comparison of Pfizer's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, Pfizer's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pfizer's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pfizer's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Pfizer's Cyclically Adjusted Price-to-FCF falls into.



Pfizer Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Pfizer's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=25.40/3.09
=8.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pfizer's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Pfizer's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.743/129.4194*129.4194
=0.743

Current CPI (Dec. 2023) = 129.4194.

Pfizer Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 0.407 99.695 0.528
201406 0.583 100.560 0.750
201409 0.609 100.428 0.785
201412 0.816 99.070 1.066
201503 0.069 99.621 0.090
201506 0.613 100.684 0.788
201509 0.752 100.392 0.969
201512 0.678 99.792 0.879
201603 0.242 100.470 0.312
201606 0.506 101.688 0.644
201609 0.700 101.861 0.889
201612 0.863 101.863 1.096
201703 0.201 102.862 0.253
201706 0.456 103.349 0.571
201709 0.710 104.136 0.882
201712 1.042 104.011 1.297
201803 0.258 105.290 0.317
201806 0.575 106.317 0.700
201809 0.785 106.507 0.954
201812 0.677 105.998 0.827
201903 0.188 107.251 0.227
201906 0.357 108.070 0.428
201909 0.681 108.329 0.814
201912 0.638 108.420 0.762
202003 0.478 108.902 0.568
202006 0.551 108.767 0.656
202009 0.281 109.815 0.331
202012 0.850 109.897 1.001
202103 0.704 111.754 0.815
202106 1.895 114.631 2.139
202109 1.784 115.734 1.995
202112 0.852 117.630 0.937
202203 1.024 121.301 1.093
202206 1.299 125.017 1.345
202209 0.898 125.227 0.928
202212 1.320 125.222 1.364
202303 0.013 127.348 0.013
202306 -0.371 128.729 -0.373
202309 0.469 129.860 0.467
202312 0.743 129.419 0.743

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Pfizer  (NYSE:PFE) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Pfizer Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Pfizer's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Pfizer (Pfizer) Business Description

Industry
Address
66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Executives
Scott Gottlieb director MOLECULAR INSIGHT PHARMACEUTICALS, 160 SECOND STREET, CAMBRIDGE MA 02142
Christoffel Boshoff officer: Executive Vice President 66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192
Jennifer B. Damico officer: SVP & Controller C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Payal Sahni officer: Executive Vice President ATTN: PFIZER CORP. SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017
Carapezzi William R Jr officer: Executive Vice President 600 MOUNTAIN AVENUE, MURRAY HILL NJ 07921
Douglas M Lankler officer: Senior Vice President PFIZER INC. ATTN: CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Mikael Dolsten officer: Senior Vice President 5 GIRALDA FARMS, MADISON NJ 07940
David M Denton officer: Chief Financial Officer & EVP 1000 LOWE'S BOULEVARD, MOORESVILLE NC 28117
William Pao officer: Executive Vice President C/O CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Michael Mcdermott officer: Executive Vice President C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, 235 EAST 42ND STREET NY 10017
Rady A Johnson officer: Executive Vice President PFIZER INC. ATTN CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Alexander R Mackenzie officer: Executive Vice President C/O PFIZER CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Sally Susman officer: Senior Vice President 767 FIFTH AVE, EOTIC LAWDER CORP, NEW YORK NY 10153
Angela Hwang officer: Group President 235 EAST 42ND STREET, ATTN: CORPORATE SECRETARY, NEW YORK NY 10017
John D Young officer: Business Unit President C/O CORPORATE SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017

Pfizer (Pfizer) Headlines

From GuruFocus

Pfizer Inc at Cowen Health Care Conference Transcript

By GuruFocus Research 01-23-2024

Pfizer Inc at Citi BioPharma Conference Transcript

By GuruFocus Research 01-23-2024

Pfizer Inc's Dividend Analysis

By GuruFocus Research 01-24-2024

Pfizer Inc at Truist BioPharma Symposium Transcript

By GuruFocus Research 01-23-2024

Pfizer Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 01-23-2024

Pfizer Inc To Acquire Seagen Inc Transcript

By GuruFocus Research 01-23-2024

Q3 2023 Pfizer Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Pfizer Inc at Wells Fargo Healthcare Conference Transcript

By GuruFocus Research 01-23-2024